Results 81 to 90 of about 19,213,336 (427)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]

open access: yes, 2019
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M   +4 more
core  

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

open access: yes, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman   +25 more
core   +3 more sources

Identification of novel small molecule inhibitors of ETS transcription factors

open access: yesFEBS Letters, EarlyView.
ETS transcription factors play an essential role in tumourigenesis and are indispensable for sprouting angiogenesis, a hallmark of cancer, which fuels tumour expansion and dissemination. Thus, targeting ETS transcription factor function could represent an effective, multifaceted strategy to block tumour growth. The evolutionarily conserved E‐Twenty‐Six
Shaima Abdalla   +9 more
wiley   +1 more source

A scoping review of patient selection methods for proton therapy

open access: yesJournal of Medical Radiation Sciences, 2022
The aim was to explore various national and international clinical decision‐making tools and dose comparison methods used for selecting cancer patients for proton versus X‐ray radiation therapy.
Nicole Zientara   +3 more
doaj   +1 more source

An ensemble of machine learning and anti-learning methods for predicting tumour patient survival rates [PDF]

open access: yes, 2016
This paper primarily addresses a dataset relating to cellular, chemical and physical conditions of patients gathered at the time they are operated upon to remove colorectal tumours. This data provides a unique insight into the biochemical and immunological status of patients at the point of tumour removal along with information about tumour ...
arxiv   +1 more source

Prostate embolization: patient selection, clinical management and results

open access: yesCVIR Endovascular, 2019
BackgroundProstate artery embolization is an emerging technique, that with the continued publication of promising data, is slowly moving from the research to the everyday clinical setting.Main bodyThis paper reviews the patient selection, clinical ...
S. Young, J. Golzarian
semanticscholar   +1 more source

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. [PDF]

open access: yes, 2017
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel.
Hoffman-Censits, Jean, Patel, Sheel
core   +3 more sources

miRNA‐29 regulates epidermal and mesenchymal functions in skin repair

open access: yesFEBS Letters, EarlyView.
miRNA‐29 inhibits cell‐to‐cell and cell‐to‐matrix adhesion by silencing mRNA targets. Adhesion is controlled by complex interactions between many types of molecules coded by mRNAs. This is crucial for keeping together the layers of the skin and for regenerating the skin after wounding.
Lalitha Thiagarajan   +10 more
wiley   +1 more source

The optimal treatment of multivessel coronary artery disease [PDF]

open access: yes, 2014
The practice of percutaneous coronary intervention has overtaken coronary bypass surgery in the treatment of ischaemic heart disease. Several randomized controlled as well as registry and observational trials have addressed the issue of patient selection
Manche, Alexander
core  

First report of multi-drug resistant tuberculosis in a systemic lupus erythematosus patient. [PDF]

open access: yes, 2015
BackgroundTreatment of a multi-drug resistant tuberculosis (MDR-TB) patient is clinically challenging, requiring a minimum of 18 months of therapy. Its occurrence in a systemic lupus erythromatosus (SLE) patient may complicate management of both MDR-TB ...
Dierberg, Kerry L   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy